Comparative Pharmacology
Head-to-head clinical analysis: IMDUR versus TRIDIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IMDUR versus TRIDIL.
IMDUR vs TRIDIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Isosorbide mononitrate is a nitrate vasodilator that relaxes vascular smooth muscle via conversion to nitric oxide (NO), which activates guanylate cyclase, increasing cGMP levels, leading to vasodilation. It primarily dilates veins (venodilation) with lesser effects on arteries, reducing preload and afterload, thereby decreasing myocardial oxygen demand.
Nitroglycerin is a vasodilator that acts directly on vascular smooth muscle, causing relaxation. It primarily dilates venous capacitance vessels, reducing preload, and at higher doses dilates arterioles, reducing afterload. The mechanism involves nitric oxide-mediated activation of guanylyl cyclase, increasing cGMP levels.
Initial: 30-60 mg orally once daily; titrate to 120 mg once daily as tolerated. Maximum: 240 mg once daily.
Initial adult dose: 5 mcg/min IV via continuous infusion, titrated by 5 mcg/min every 3-5 minutes to achieve desired effect; usual therapeutic range 10-200 mcg/min.
None Documented
None Documented
Terminal elimination half-life of isosorbide mononitrate is approximately 5 hours. This supports once-daily dosing for IMDUR (extended-release formulation) due to prolonged absorption phase.
Terminal elimination half-life of nitroglycerin is 1-4 minutes; clinical effects are limited by rapid metabolism
Isosorbide dinitrate (IMDUR active metabolite? Actually IMDUR is isosorbide mononitrate, the active metabolite of isosorbide dinitrate. For isosorbide mononitrate: renal excretion is approximately 96% as metabolites, with about 2% unchanged; biliary/fecal excretion is minimal, <2%.
Renal (87% as inorganic nitrite/nitrate and metabolites), biliary/fecal (minimal, <1%)
Category C
Category C
Nitrate Vasodilator
Nitrate Vasodilator